Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 BiTEs better than CAR T cells.

Literature DB >> 33496755

BiTEs better than CAR T cells.

Marion Subklewe.

Abstract

This article has a companion Point by Molina and Shah.

Entities: Disease

Mesh：
T-Lymphocytes

Year: 2021 PMID： 33496755 PMCID： PMC7839370 DOI： 10.1182/bloodadvances.2020001792

Source DB: PubMed Journal: Blood Adv ISSN： 2473-9529

43 in total

1. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors: Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz
Journal: N Engl J Med Date: 2018-12-01 Impact factor: 91.245

2. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.

Authors: Hagop Kantarjian; Anthony Stein; Nicola Gökbuget; Adele K Fielding; Andre C Schuh; Josep-Maria Ribera; Andrew Wei; Hervé Dombret; Robin Foà; Renato Bassan; Önder Arslan; Miguel A Sanz; Julie Bergeron; Fatih Demirkan; Ewa Lech-Maranda; Alessandro Rambaldi; Xavier Thomas; Heinz-August Horst; Monika Brüggemann; Wolfram Klapper; Brent L Wood; Alex Fleishman; Dirk Nagorsen; Christopher Holland; Zachary Zimmerman; Max S Topp
Journal: N Engl J Med Date: 2017-03-02 Impact factor: 91.245

Review 3. Mechanisms of resistance to CAR T cell therapy.

Authors: Nirali N Shah; Terry J Fry
Journal: Nat Rev Clin Oncol Date: 2019-06 Impact factor: 66.675

4. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells.

Authors: Takahiro Kamiya; Desmond Wong; Yi Tian Png; Dario Campana
Journal: Blood Adv Date: 2018-03-13

5. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.

Authors: Justin Eyquem; Jorge Mansilla-Soto; Theodoros Giavridis; Sjoukje J C van der Stegen; Mohamad Hamieh; Kristen M Cunanan; Ashlesha Odak; Mithat Gönen; Michel Sadelain
Journal: Nature Date: 2017-02-22 Impact factor: 49.962

6. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.

Authors: Monika Herrmann; Christina Krupka; Katrin Deiser; Bettina Brauchle; Anetta Marcinek; Ana Ogrinc Wagner; Felicitas Rataj; Ralph Mocikat; Klaus H Metzeler; Karsten Spiekermann; Sebastian Kobold; Nadja C Fenn; Karl-Peter Hopfner; Marion Subklewe
Journal: Blood Date: 2018-10-01 Impact factor: 22.113

7. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.

Authors: Elena J Orlando; Xia Han; Catherine Tribouley; Patricia A Wood; Rebecca J Leary; Markus Riester; John E Levine; Muna Qayed; Stephan A Grupp; Michael Boyer; Barbara De Moerloose; Eneida R Nemecek; Henrique Bittencourt; Hidefumi Hiramatsu; Jochen Buechner; Stella M Davies; Michael R Verneris; Kevin Nguyen; Jennifer L Brogdon; Hans Bitter; Michael Morrissey; Piotr Pierog; Serafino Pantano; Jeffrey A Engelman; Wendy Winckler
Journal: Nat Med Date: 2018-10-01 Impact factor: 53.440

Review 8. Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies.

Authors: Marco Ruella; Marcela V Maus
Journal: Comput Struct Biotechnol J Date: 2016-09-28 Impact factor: 7.271

9. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.

Authors: Judith Feucht; Simone Kayser; David Gorodezki; Mohamad Hamieh; Michaela Döring; Franziska Blaeschke; Patrick Schlegel; Hans Bösmüller; Leticia Quintanilla-Fend; Martin Ebinger; Peter Lang; Rupert Handgretinger; Tobias Feuchtinger
Journal: Oncotarget Date: 2016-11-22

10. Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.

Authors: Nicola Gökbuget; Hervé Dombret; Sebastian Giebel; Monika Brüggemann; Michael Doubek; Robin Foa; Dieter Hoelzer; Christopher Kim; Giovanni Martinelli; Elena Parovichnikova; Josep Maria Ribera; Marieke Schoonen; Catherine Tuglus; Gerhard Zugmaier; Renato Bassan
Journal: Eur J Haematol Date: 2020-01-24 Impact factor: 2.997

16 in total

1. Relapsed disease: off-the-shelf immunotherapies vs customized engineered products.

Authors: Reem Karmali
Journal: Hematology Am Soc Hematol Educ Program Date: 2021-12-10

Review 2. Empowering patients from within: Emerging nanomedicines for in vivo immune cell reprogramming.

Authors: Matthias T Stephan
Journal: Semin Immunol Date: 2021-11-26 Impact factor: 11.130

Review 3. Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice.

Authors: Ajeet Gajra; Abigail Zalenski; Aishwarya Sannareddy; Yolaine Jeune-Smith; Kandice Kapinos; Ankit Kansagra
Journal: Pharmaceut Med Date: 2022-06-07

Review 4. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?

Authors: David Kegyes; Catalin Constantinescu; Louise Vrancken; Leo Rasche; Celine Gregoire; Bogdan Tigu; Diana Gulei; Delia Dima; Alina Tanase; Hermann Einsele; Stefan Ciurea; Ciprian Tomuleasa; Jo Caers
Journal: J Hematol Oncol Date: 2022-06-07 Impact factor: 23.168

Review 5. Adverse Cardiac Effects of CAR T-Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions.

Authors: Prarthana J Dalal; Nikita P Patel; Matthew J Feinstein; Nausheen Akhter
Journal: Technol Cancer Res Treat Date: 2022 Jan-Dec